홈 › 다발성 골수종 › 유타 › Salt Lake City
UT Salt Lake City의 다발성 골수종 임상 시험
다발성 골수종 관련 연구 21개가 Salt Lake City 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
피험자 모집 중3상
- Research Site, Salt Lake City
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
피험자 모집 중1/2상
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중3상
- Huntsman Cancer Institute, Salt Lake City
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중3상
- Utah Cancer Specialists, Salt Lake City
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
피험자 모집 중3상
- LDS Hospital, Salt Lake City
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
피험자 모집 중3상
- Utah Cancer Specialists, Salt Lake City
- Huntsman Cancer Institute, Salt Lake City
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
피험자 모집 중2상
- Intermountain Healthcare, Salt Lake City
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
피험자 모집 중3상
- Huntsman Cancer Institute, Salt Lake City
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
피험자 모집 중2상
- LDS Hospital, Salt Lake City
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
피험자 모집 중1/2상
- Huntsman Cancer Institute /ID# 271618, Salt Lake City
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
피험자 모집 중2상
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
피험자 모집 중2상
- Huntsman Cancer Institute, Salt Lake City
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
피험자 모집 중1/2상
- Research Site, Salt Lake City
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
피험자 모집 중1상
- Huntsman Cancer Institute, University of Utah, Salt Lake City
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
피험자 모집 중1/2상
- Huntsman Cancer Institute /ID# 272575, Salt Lake City
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
피험자 모집 중2상
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
피험자 모집 중1상
- Huntsman Cancer Center Institute University of Utah, Salt Lake City
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
피험자 모집 중1상
- University of Utah, Salt Lake City
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
피험자 모집 중1/2상
- Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare, Salt Lake City
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
피험자 모집 중관찰 연구
- Huntsman Cancer Institute at the University of Utah, Salt Lake City
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
피험자 모집 중1상
- Huntsman Cancer Institute, University of Utah, Salt Lake City
다른 도시의 다발성 골수종 시험
- New York City, NY연구 60개
- Boston, MA연구 42개
- Atlanta, GA연구 42개
- Houston, TX연구 38개
- Durham, NC연구 37개
- Nashville, TN연구 32개
- Denver, CO연구 27개
- Rochester, MN연구 24개
- St. Louis, MO연구 24개
- Columbus, OH연구 24개
- Baldwin Park, CA연구 23개
- Edison, NJ연구 22개
Salt Lake City의 다른 연구
- 비소세포폐암연구 31개
- 암 (전체)연구 27개
- 유방암연구 27개
- 대장직장암연구 22개
- 폐암연구 21개
- 흑색종연구 21개
- 전이성 암연구 20개
- 난소암연구 19개
- 비만연구 18개
- 급성 골수성 백혈병연구 17개
- 심부전연구 17개
- 전립선암연구 15개
ClinicalTrials.gov 출처, 2026. 10. 6. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.